Orphan Drugs Market Size, Share & Trends Analysis Report By Drug Type (Biological, Non-Biological), By Top Selling Drugs, By Therapy Area (Oncology, Blood, Central Nervous System, Endocrine, Respiratory, Immunomodulatory, Other Disease Types), By Region, And By Segment Forecasts, 2024-2031

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Orphan Drugs Market Snapshot

Chapter 4. Global Orphan Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. Clinical Trial/Pipeline Analysis Snapshot

4.8. COVID 19 Impact on Pharmaceutical Industry

Chapter 5. Market Segmentation 1: Drug Types Estimates & Trend Analysis

5.1. Drug Types & Market Share, 2019 & 2031

5.2. Market Size (Value) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Types:

5.2.1. Biological

5.2.2. Non-Biological

Chapter 6. Market Segmentation 2: Top Selling Drugs & Trend Analysis

6.1. Top Selling Drugs & Market Share, 2019 & 2031

6.2. Market Size (Value)& Forecasts and Trend Analyses, 2019 to 2031 for the following Top Selling Drugs:

6.2.1. Revlimid

6.2.2. Rituxan

6.2.3. Copaxone

6.2.4. Opdivo

6.2.5. Keytruda

6.2.6. Imbruvica

6.2.7. Avonex

6.2.8. Sensipar

6.2.9. Soliris

6.2.10. Other Top Selling Drugs

Chapter 7. Market Segmentation 3: Therapy Area & Trend Analysis

7.1. Therapy Area & Market Share, 2019 & 2031

7.2. Market Size (Value)& Forecasts and Trend Analyses, 2019 to 2031 for the following Therapy Area

7.2.1. Oncology

7.2.2. Blood

7.2.3. Central Nervous System

7.2.4. Endocrine

7.2.5. Cardiovascular

7.2.6. Respiratory

7.2.7. Immunomodulatory

7.2.8. Other Disease Types

Chapter 8. Orphan Drugs Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2024-2031

8.1.2. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2024-2031

8.1.3. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2024-2031

8.1.4. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by country, 2024-2031

8.1.4.1. U.S.

8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Drug Types, 2024-2031

8.2.2. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2024-2031

8.2.3. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2024-2031

8.2.4. Europe Orphan Drugs Market revenue (US$ Million) by country, 2024-2031

8.2.4.1. Germany

8.2.4.2. Poland

8.2.4.3. France

8.2.4.4. Italy

8.2.4.5. Spain

8.2.4.6. UK

8.2.4.7. Rest of Europe

 8.3. Asia Pacific

8.3.1. Asia Pacific Orphan Drugs Market revenue (US$ Million) Drug Types, 2024-2031

8.3.2. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2024-2031

8.3.3. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2024-2031

8.3.4. Asia Pacific Orphan Drugs Market revenue (US$ Million) by country, 2024-2031

8.3.4.1. China

8.3.4.2. India

8.3.4.3. Japan

8.3.4.4. Australia

8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America Orphan Drugs Market revenue (US$ Million) Drug Types, 2024-2031

8.4.2. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2024-2031

8.4.3. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2024-2031

8.4.4. Latin America Orphan Drugs Market revenue (US$ Million) by country, 2024-2031

8.4.4.1. Brazil

8.4.4.2. Rest of Latin America

8.5. MEA

8.5.1. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2024-2031

8.5.2. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2024-2031

8.5.3. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2024-2031

8.5.4. MEA revenue Orphan Drugs Market revenue (US$ Million) by country, (US$ Million) 2024-2031

8.5.4.1. South Africa

8.5.4.2. Rest of MEA

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Bristol-Myers Squibb Company

9.2.2. Celgene Corporation

9.2.3. F. Hoffmann-La Roche Ltd

9.2.4. Amgen

9.2.5. Biogen

9.2.6. Bayer

9.2.7. Novartis AG

9.2.8. GlaxoSmithKline plc

9.2.9. Johnson & Johnson

9.2.10. AbbVie Inc

9.2.11. Eli Lilly and Company

9.2.12. Alexion Pharmaceuticals

9.2.13. Shire

9.2.14. Novo Nordisk

9.2.15. AstraZeneca

9.2.16. Eisai

9.2.17. Daiichi Sankyo

9.2.18. Merck

9.2.19. Teva Pharmaceutical Industries

9.2.20. Actelion Pharmaceuticals Ltd.

9.2.21. Aegerion Pharmaceuticals

Other Prominent Players

Global Orphan Drugs Market Segmentation:

Global Orphan Drugs Market Revenue by Drug Types

• Biological
• Non-Biological

Global Orphan Drugs Market Revenue Based on Top Selling Drugs

• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Other Top Selling Drugs

Global Orphan Drugs Market Revenue Based on Therapy Area

• Oncology
• Blood
• Central Nervous System
• Endocrine
• Cardiovascular
• Respiratory
• Immunomodulatory
• Other Disease Types

Global Orphan Drugs Market Revenue Based on Region

Europe Orphan Drugs Market Revenue by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

North America Orphan Drugs Market Revenue by Country

• U.S.
• Canada

Asia Pacific Orphan Drugs Market Revenue by Country

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Orphan Drugs Market Revenue by Country

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Orphan Drugs Market Revenue by Country

• GCC Countries
• South Africa
• Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

• Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
• External and internal proprietary databases, regulatory databases, and relevant patent analysis
• Statistical databases, National government documents, and market reports
• Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

• Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
• Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
• Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
• End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.